

Emergence of *Clostridium difficile* Ribotype 027 in Korea

Heejung Kim, M.D.¹, Yangsoon Lee, M.D.¹, Hee-Won Moon, M.D.², Chae Seung Lim, M.D.³, Kyungwon Lee, M.D.¹,
and Yunsop Chong, M.D.¹

Department of Laboratory Medicine and Research Institute of Bacterial Resistance¹, Yonsei University College of Medicine, Seoul; Department of Laboratory Medicine², Konkuk University School of Medicine, Seoul; Department of Laboratory Medicine³, Korea University College of Medicine, Seoul, Korea

Background: *Clostridium difficile* infection (CDI) has markedly risen and is associated with hypervirulent ribotype 027 outbreaks in North America and Europe since 2003. The aims of this study were to determine the prevalence of ribotype 027 among *C. difficile* isolates in Korea, to characterize the ribotype 027 isolates, and to determine the clinical severity of CDI in patients infected with these isolates.

Methods: A total of 1,251 isolates of *C. difficile* recovered from stool specimens of suspected CDI patients at two tertiary-care hospitals and one commercial laboratory between 2002 and 2009. Genes for toxin A (*tcdA*), toxin B (*tcdB*), and binary toxin (*cdtA* and *cdtB*) were detected by PCR. Mutation in the *tcdC* gene was detected by sequencing after PCR amplification. For molecular genotyping, we performed PCR-ribotyping, pulsed-field gel electrophoresis (PFGE), and multilocus variable-number tandem-repeat analysis (MLVA). Minimum inhibitory concentrations of moxifloxacin were determined using Etest strips (AB bioMérieux, Sweden). **Results:** We identified 7 isolates as ribotype 027. These isolates had the same *tcdC* mutation as the epidemic strain, and 6 of them were resistant to moxifloxacin. The isolates were categorized into 3 different PFGE types and 7 different MLVA types. All the 7 cases had occurred sporadically.

Conclusions: *C. difficile* ribotype 027 is uncommon, but it has emerged in Korea. The spread of this ribotype should be closely monitored in order to avoid an outbreak of CDI in Korea.

Key Words: *Clostridium difficile*, PCR-ribotype 027, Pulsed-field gel electrophoresis, Multilocus variable-number tandem-repeat analysis

INTRODUCTION

Severe *Clostridium difficile* infections (CDIs) associated with an emerging epidemic strain, PCR-ribotype 027, have increased in frequency and severity in the U.S., Canada, and the European countries since 2003 [1]. However, reports of ribotype 027 infections in East Asian countries remain rare

[2]. One case each was reported from Japan [3] and Korea [4] in 2007 and 2009, respectively. A one-year surveillance study between 2007 and 2008 in Shanghai, China failed to detect any cases, although one case was reported in Hong Kong in 2009 [2]. These results may indicate the onset of spreading ribotype 027 infection in Asian countries.

Ribotype 027 strain had toxin A, toxin B and binary toxin with deletion of toxin regulator gene (*tcdC*) [1]. According to a previous study, the use of moxifloxacin is associated with ribotype 027 outbreaks, and the isolates obtained in that study were resistant to levofloxacin and moxifloxacin [5]. A Korean isolate was resistant, whereas 1 Japanese isolate was susceptible to moxifloxacin [3, 4]; this indicated a need for further testing of Korean isolates.

The aims of this study were to determine the prevalence of ribotype 027 among the stored *C. difficile* isolates, to characterize the ribotype 027 isolates, and to evaluate the clinical severity of CDI in patients infected with these strains.

Received: January 14, 2011

Manuscript No: KJLM-11-004

Revision received: April 18, 2011

Accepted: April 19, 2011

Corresponding author: Kyungwon Lee, M.D.

Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea

Tel: +82-2-2228-2446, Fax: +82-2-313-0908, E-mail: leekcp@yuhs.ac

ISSN 1598-6535 © The Korean Society for Laboratory Medicine.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

METHODS

1. Bacterial isolates and antimicrobial susceptibility testing

A total of 1,251 *C. difficile* isolates were recovered from stool specimens of suspected CDI patients at two tertiary-care hospitals and one commercial laboratory between 2002 and 2009. The commercial laboratory processed the stool specimens collected from hospitals and clinics without in-house anaerobic microbiological testing facilities. *C. difficile* selective agar (CDSA; Becton, Dickinson and Company, Franklin Lakes, NJ, USA) was used to isolate *C. difficile* under anaerobic incubation. The isolates were identified using conventional tests and the ATB 32A system (bioMérieux, Marcy l’Etoile, France). Minimum inhibitory concentrations (MICs) of moxifloxacin for ribotype 027 isolates were determined using Etest strips (AB bioMérieux, Solna, Sweden).

2. Clinical characteristics of patients

We reviewed the patients’ medical records, and according to the criteria proposed by Zar et al. [6], patients with ≥ 2 points were considered to have severe CDI. One point was given for each of the following criteria: age > 60 yr, body temperature $> 38.3^\circ\text{C}$, serum albumin < 2.5 mg/dL, and peripheral white blood cell count $> 15,000/\mu\text{L}$. Two points were given if there was endoscopic evidence of pseudo-membranous colitis (PMC) or if the patient was admitted to the intensive care unit.

3. PCR assay for toxin genes

C. difficile toxin genes were detected by performing PCR as described in previous studies [7, 8]. Primer sequences used in this study are listed in Table 1. *C. difficile* VPI 10463 (A⁺B⁺, CDT⁻), 3608/03 (A⁻B⁻, CDT⁻), SE844 (A⁺B⁺, CDT⁺), and 1470 (A⁻B⁺, CDT⁻) were used as controls for the PCR assays. The obtained amplicons were commercially sequenced (Macrogen, Seoul, Korea). The deduced amino acid sequences were compared to those of the strain VPI 10463.

4. PCR-ribotyping

PCR-ribotyping was performed according to a previously described method [9] with minor modification. We added 10 μL of crude nucleic acid as template to a 50- μL PCR mixture containing 10 mM Tris-HCl (pH 8.3) and 50 mM KCl (GeneAmp 1 \times PCR Buffer II; Applied Biosystems, Foster City, CA, USA), 4.0 mM MgCl₂, 0.4 mM dNTP, 1.5 U Taq DNA polymerase (AmpliTaq Gold, Applied Biosystems), and 0.4 μM primers (CD1 and CD1445).

Table 1. Primers used in this study

Test	Target	Primer	Oligonucleotide sequence (5'→3')	Reference
Toxin genes	<i>tcdA</i>	NK9	CCACCAGCTGCAGCCATA	[7]
	rep	NK11	TGATGCTAATAATGAATCTAAAATGGTAAC	
	<i>tcdB</i>	NK104	GTGTAGCAATGAAAGTCCAAGTTTACGC	
		NK105	CACCTAGCTCTTTGATTGCTGCACCT	
	<i>cdtA</i>	cdtA pos	TGAACCTGAAAAGGTGATG	
		cdtA rev	AGGATTATTACTGGACCATTGG	
	<i>cdtB</i>	cdtB pos	CTTAATGCAAGTAAATACTGAG	
		cdtB rev	AACGGATCTCTTGCTCAGTC	
PCR	16S-23S	CD1	GCGCCCTTTGTAGCTTGACC	[9]
ribotyping	rRNA	CD1445	CTGGGGTGAAGTCGTAACAAGG	
<i>tcdC</i>	<i>tcdC</i>	PaL15	TCTCTACAGCTATCCCTGGT	[8]
		PaL16	AAAAATGAGGGTAAACGAATTT	
MLVA	CDR4F		ATTAATCATATCCTACAGAACACGA	[12]
	CDR4R		TAAAAACAAATGATATAAACTGAAAAG	
	CDR5F		AATTTTAAGTTAACGTTTTTCTACAT	
	CDR5R		AGCCATTTTTATCAATCCTTTCTAT	
	CDR9F		TCTGGGATGTAAGTAGGCACTTGT	
	CDR9R		TCTGGGATGTAAGTAGGCACTTGT	
	CDR48F		AGGAGCTTTATATGGACATTCAGGTAG	
	CDR48R		AATCTCTTCAAACCTCTCAATCTCAAT	
	CDR49F		AACATATTAGGCAATTTAGTC	
	CDR49R		GAGTATTATTATCATTGTGGGTATTA	
	CDR59F		GTAGAAGGGGCAAATAATGAG	
	CDR59R		CCTTCTGGCTTCTTGTA ATA	
	CDR60F		GGTGCACATGCTGGTCTCG	
	CDR60R		AACGCATTAATTTCACTCTCCTAC	

Abbreviations: MLVA, multilocus variable-number tandem-repeat analysis; CDR, *Clostridium difficile* repeat.

5. Pulsed-field gel electrophoresis and multilocus variable-number tandem-repeat analysis typing

Pulsed-field gel electrophoresis (PFGE) analysis was performed by modified method of Alonso et al. [10]. In brief, we prepared plugs of chromosomal DNA from fresh colonies cultured for 24 hr and treated them with high concentration of proteinase K (75 U/mL). Thiourea was added to the gel and running buffer used for PFGE [11].

Multilocus variable-number tandem-repeat analysis (MLVA) was performed by PCR amplification and sequence analysis of 7 selected *C. difficile* repeat (CDR) loci; CDR4, CDR5, CDR9, CDR48, CDR49, CDR59, and CDR60. The primer sets used are listed in Table 1 [12]. The copy numbers of each of the 7 CDR loci were concatenated to generate an MLVA type for each isolate.

RESULTS

Of the 1,251 *C. difficile* isolates, 47 (3.8%) were PCR positive for the toxin A, toxin B, and binary toxin genes, and 7 (0.6%) were identified as ribotype 027 by PCR-ribotyping. The first isolate to be identified as ribotype 027 was from a sample obtained in 2006, and the prevalence of ribotype 027 was 0.6% in 2006 and 2007, 0.9% in 2008, and 1.0% in 2009 (Table 2).

All the ribotype 027 isolates had an 18-bp deletion from position 330 to 347 and a 1-bp deletion at position 117 in the *tcdC* gene sequence. We observed identical PFGE patterns for 5 isolates (isolates 1, 4, 5, 6, and 7). However, the patterns for isolates 2 and 3 differed from those of the other isolates in 3 and 2 bands, respectively (Table 3, Fig. 1).

All the 7 isolates had different MLVA types. However, all the isolates had the same number of variable number tandem

Table 2. Prevalence of binary toxin-producing *Clostridium difficile* and PCR-ribotype 027

Year	N of isolates			Total	Binary toxin (+)		Ribotype 027	
	S hospital	Y hospital	Commercial Lab.		N	%	N	%
2002	179	ND	ND	179	3	1.7	0	0.0
2003	107	ND	ND	107	0	0.0	0	0.0
2004	53	ND	ND	53	1	1.9	0	0.0
2005	40	2	ND	42	1	2.4	0	0.0
2006	155	19	ND	174	10	5.7	1	0.6
2007	145	13	ND	158	10	6.3	1	0.6
2008	162	58	109	329	12	3.6	3	0.9
2009 (Jan–Jun)	98	23	88	209	10	4.8	2	1.0
Total	939	115	197	1,251	47	3.8	7	0.6

Abbreviation: ND, not done.

Table 3. Molecular and phenotypic characteristics of the *Clostridium difficile* PCR-ribotype 027

No. of isolate	Year of isolation	Hospital*	PFGE type	MLVA (N of VNTRs for each CDR locus)								MIC of moxifloxacin (µg/mL)
				CD R 4	CD R 5	CD R 9	CD R 48	CD R 49	CD R 59	CD R 60		
1	2006	Y	I	20	3	14	9	12	1	12	> 32	
2	2007	S	III	33	3	12	8	11	1	11	0.5	
3	2008	K	II	29	3	14	9	13	1	9	> 32	
4	2008	K	I	20	3	15	9	12	1	10	> 32	
5	2008	G	I	17	3	14	9	12	1	10	> 32	
6	2009	Y	I	23	3	14	9	13	1	10	> 32	
7	2009	S	I	25	3	16	10	12	1	9	> 32	

*Two hospitals, hospitals K and G, sent the samples to a commercial laboratory, and the samples were redirected to the S hospital in Seoul where the test was performed.

Abbreviations: PFGE, pulsed-field gel electrophoresis; MLVA, multilocus variable-number tandem-repeat analysis; VNTR, variable number tandem repeat; CDR, *C. difficile* repeat; MIC, minimum inhibitory concentration.

repeats (VNTRs) at the CDR5 and CDR59 loci (Table 3).

The MIC of moxifloxacin was >32 µg/mL for 6 of the 7 isolates and 0.5 µg/mL for the remaining 1 isolate (isolate 2).

Brief histories of patients infected with ribotype 027 are summarized in Table 4. The ages of the 7 patients (2 men and 5 women) were in the range of 25 to 88 yr, except a clinically-irrelevant 40-day-old infant with acute gastroenteritis.

All patients had been hospitalized for some underlying diseases. Four patients had received anti-tuberculous medication 2-4 weeks before hospitalization. None of the pa-




Fig. 1. Pulsed-field gel electrophoresis (PFGE) patterns of *SmaI*-digested genomic DNA obtained from the ribotype 027 isolates. Lanes 1 and 9 were loaded with a 50-kb ladder (molecular marker). The PFGE patterns for isolates 2 and 3 differed in 5 bands. The remaining 5 isolates had identical patterns, and their pattern differed from that of isolates 2 and 3 in 3 and 2 bands, respectively.

Table 4. Clinical features of patients infected with the *Clostridium difficile* PCR-ribotype O27

No. of patient	N of days from admission to isolation	Duration of admission	Age/Gender	Underlying disease	Previous therapy	Diarrhea times/day	WBC (/ μ L)	Serum albumin (mg/dL)	Colonoscopy/Biopsy	Treatments	Outcome
1	1 day (had previous admission history)	26 May-1 Jun 2006	88 yr/F	Pulmonary tuberculosis	HERZ for 2 mo	3-4	4,900	3.3	Suspected ulcerative colitis, infectious colitis/Within normal limit	Ceftriaxone	Improved
2	5 days	30 Mar-24 Apr 2007	25 yr/F	CRF, AV fistular infection	Cefobactam/vancomycin for 20 days	5-10	17,180	2.1	Suspected Pseudomembranous colitis/Chronic nonspecific inflammation	Metronidazole	Improved
3	16 days	30 Jun-22 Jul 2008	73 yr/F	CLL, pulmonary tuberculosis	HERZ for 3 mo, Fludarabine + cyclophosphamide for 3 days, gancyclovir for 2 wk, cefepime+metronidazole for 2 wk	Over 10	730	3.0	NT	Cefepime, metronidazole	Improved
4	86 days	4 Aug-18 Nov 2008	53 yr/M	Wound infection (MRSA)	Vancomycin for 4 mo, ciprofloxacin for 1 wk	5-10	7,200	3.0	NT	Metronidazole, vancomycin	Recurred
5	14 days	18 Nov-11 Dec 2008	40 days/M	Acute gastroenteritis	Data not available	5-10	7,790	3.8	NT	Amikacin, piperacillin -tazobactam	Not applicable
6	2 days	16 Mar-20 Mar 2009	62 yr/F	Tuberculous lymphadenitis	HERZ for 3 mo	5-10	7,600	4.1	Infectious colitis/ Increased number of plasma cells in the lamina propria	Ciprofloxacin	Improved
7	28 days	19 Mar-28 Apr 2009	82 yr/F	Pulmonary tuberculosis	HERZ for 2 mo	5-10	9,630	2.9	Pseudomembranous colitis/ Acute colitis, active	Metronidazole, vancomycin	Recurred

Abbreviations: WBC, white blood cell; HERZ, isoniazid, ethambutol, rifampin, pyrazinamide; mo, month; CRF, chronic renal failure; AV, arteriovenous; NT, not tested; MRSA, methicillin-resistant *Staphylococcus aureus*; HER, isoniazid, ethambutol, rifampin.

tients had travelled overseas. Symptoms and their severity varied among the patients, ranging from mild colitis to severe PMC. Except for patient 2, none of the patients showed high fever ($>38.0^{\circ}\text{C}$), increased leukocyte count ($>15,000/\mu\text{L}$), increased serum creatinine ($>2.0\text{ mg/dL}$), or decreased serum albumin ($<2.5\text{ mg/dL}$). Patient 2 showed high leukocyte count and serum creatinine level due to underlying chronic renal failure and an arteriovenous fistula infection.

Two (patient nos. 2 and 7) cases were diagnosed with suspected PMC and PMC by colonoscopic biopsy and considered probably severe (patient no. 2) or severe (patient no. 7) according to the criteria proposed by Zar FA et al. [6].

Metronidazole was administered to 4 patients (patient nos. 2, 3, 4, and 7) to treat CDI. Because of poor response, for patients 4 and 7, the regimen was changed to vancomycin, but the infection recurred. Two patients (patient nos. 1 and 6) recovered without CDI treatment.

DISCUSSION

Although the first case of ribotype 027 infection in Korea was reported in 2009 [4], we found that ribotype 027 was present in Korea as early as 2006. Since 2006, the prevalence of ribotype 027 isolates has been 0.8% (7/870). Except for patient no. 6, all the patients had most likely acquired the infection in a hospital. We recovered these isolates from 7 patients who had visited 4 different hospitals located in Seoul and Gyeonggi province; this indicated an early stage of dissemination to Korean hospitals. Two of these hospitals sent the samples to a commercial laboratory for culturing *C. difficile*, and the samples were redirected to the S hospital in Seoul where the tests were performed. The presence of ribotype 027 in an infant was clinically irrelevant; however, this finding suggested that the isolate was easily transmissible.

Severe diseases are more likely to be caused by ribotype 027 strains than by non-027 strains, because the ribotype 027 strains produces excessive amounts of toxins A and B as a result of *tcdC* deletion [5]. There is no consensus about the definition of severe CDI. However, as per the criteria proposed by Zar et al. [6], 2 of the 7 cases in this study, like the first case reported in Korea [4], were either probably severe (case no. 2) or severe (case no. 7). In North America, patients infected with the ribotype 027 isolates had severe symptoms more frequently; however, a study in England showed no such evidence [13].

Mortality due to ribotype 027 infection increases with the patient's age. In a Canadian study, 44.1% of the patients were older than 65 yr, and 8.1% of them died within 30 days after diagnosis [14]. In our study, 3 out of 7 patients (42.8%) were

older than 65 yr, and none of them died from CDI.

Anti-tuberculous agents are rarely associated with CDI. Among these agents, only rifampin is considered a cause of CDIs because rifampin has an antibiotic effect on a wide range of bacteria, whereas isoniazid and ethambutol have little or no activity against anaerobes [15]. In our study, 4 patients had received rifampin.

In our study, 6 of the 7 isolates were resistant to moxifloxacin; this was also true for the recent epidemic-causing PCR-ribotype 027 strains isolated in other countries. In contrast, the PCR-ribotype 027 strains isolated prior to 2001 were susceptible to moxifloxacin [5].

PFGE patterns of 5 isolates (1, 4, 5, 6, and 7) were identical. Compared to the pattern of these 5 isolates, the pattern for isolates 2 and 3 differed in 3 and 2 bands, respectively (Fig. 1). All the isolates were categorized as different MLVA types. The VNTR loci used to discriminate these isolates were CDR4, CDR9, CD48, CDR49, and CDR60. MLVA typing indicated that these isolates were not clones. All the 7 cases had occurred sporadically.

For differentiating the isolates, MLVA was more useful than PFGE.

C. difficile ribotype 027 is uncommon, but it has emerged in Korea. The spread of this ribotype should be closely monitored in order to avoid an outbreak of CDI in Korea.

Authors' Disclosures of Potential Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgement

This study was supported by a faculty research grant from Yonsei University College of Medicine (grant 6-2008-0269). We thank Thomas V. Reily (University of Western Australia, Perth, WA, Australia) for providing reference strains and Myungsook Kim (Yonsei University Health System, Seoul, Korea), Kwangwoo Kim (Yonsei University Health System, Seoul, Korea), and Gwanghee Byun (Kyunghee University, Yongin, Korea) for laboratory assistance.

REFERENCES

- Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *Lancet* 2005;366:1079-84.
- Cheng VC, Yam WC, Chan JF, To KK, Ho PL, Yuen KY. *Clostridium difficile* ribotype 027 arrives in Hong Kong. *Int J Antimicrob Agents* 2009;34:492-3.
- Kato H, Ito Y, van den Berg RJ, Kuijper EJ, Arakawa Y. First isola-

- tion of *Clostridium difficile* 027 in Japan. Euro Surveill 2007;12:E070111.3.
4. Tae CH, Jung SA, Song HJ, Kim SE, Choi HJ, Lee M, et al. The first case of antibiotic-associated colitis by *Clostridium difficile* PCR ribotype 027 in Korea. J Korean Med Sci 2009;24:520-4.
 5. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of *Clostridium difficile*. N Engl J Med 2005;353:2433-41.
 6. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.
 7. Terhes G, Urbán E, Sóki J, Hamid KA, Nagy E. Community-acquired *Clostridium difficile* diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol 2004;42:4316-8.
 8. Spigaglia P and Mastrantonio P. Comparative analysis of *Clostridium difficile* clinical isolates belonging to different genetic lineages and time periods. J Med Microbiol 2004;53:1129-36.
 9. O'Neill GL, Ogunisola FT, Brazier JS, Duerden BI. Modification of a PCR ribotyping method for application as a routine typing scheme for *Clostridium difficile*. Anaerobe 1996;2:205-9.
 10. Alonso R, Martín A, Peláez T, Marín M, Rodríguez-Creixéms M, Bouza E. An improved protocol for pulsed-field gel electrophoresis typing of *Clostridium difficile*. J Med Microbiol 2005;54:155-7.
 11. Kim SJ, Kim H, Seo Y, Yong D, Jeong SH, Chong Y, et al. Molecular characterization of toxin A-negative, toxin B-positive variant strains of *Clostridium difficile* isolated in Korea. Diagn Microbiol Infect Dis 2010;67:198-201.
 12. Marsh JW, O'Leary MM, Shutt KA, Pasculle AW, Johnson S, Gerding DN, et al. Multilocus variable-number tandem-repeat analysis for investigation of *Clostridium difficile* transmission in Hospitals. J Clin Microbiol 2006;44:2558-66.
 13. Morgan OW, Rodrigues B, Elston T, Verlander NQ, Brown DF, Brazier J, et al. Clinical severity of *Clostridium difficile* PCR ribotype 027: a case-case study. PLoS One 2008;3:e1812.
 14. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. *Clostridium difficile*-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466-72.
 15. Jung SW, Jeon SW, Do BH, Kim SG, Ha SS, Cho CM, et al. Clinical aspects of rifampicin-associated pseudomembranous colitis. J Clin Gastroenterol 2007;41:38-40.